Genprex presents positive preclinical research from studies of GPX-002

Genprex (GNPX) announced that its research collaborators presented positive preclinical research from studies of GPX-002, the company’s diabetes gene therapy drug candidate, at the 2025 American Diabetes Association 85th Scientific Session in Chicago. “We are proud of the research presented at the ADA conference, which demonstrates that alpha cells in animal models of T1D have undergone transdifferentiation to beta-like cells after being transduced with GPX-002. In addition, the beta-like cells were still providing improved control of glucose levels after three months,” said Ryan Confer, President and CEO at Genprex. “We are very excited to continue evaluating GPX-002 as we further optimize how to control anti-viral immunity and move toward human clinical trials.”